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Abstract 
Introduction: Antiangiogenic approaches are currently the dominating experimental 
therapeutic strategy in glioblastoma. First enthusiasm was provoked by promising radiological 
response rates and an apparent clinical benefit with some of these agents. Major limitations 
include the modest number of durable responses, the lack of cytotoxic antitumor activity, of 
synergy when combined with chemotherapy and of an overall survival benefit.  
Areas covered: We review the rationale as well as preclinical and clinical evidence for the 
future development of antiangiogenic agents in glioblastoma. The most prominent approach 
targets vascular endothelial growth factor (VEGF) and includes agents such as the VEGF 
antibody bevacizumab, the VEGF receptor fusion protein aflibercept, or the tyrosine kinase 
inhibitors cediranib and XL-184. Inhibition of angiogenic pathways by small molecules, e.g. 
enzastaurin, or anti-integrin based approaches, e.g. cilengitide, represent alternative strategies. 
Expert opinion: Enzastaurin and cediranib failed in randomized phase III trials in recurrent 
glioblastoma, aflibercept in phase II. In contrast, bevacizumab was conditionally approved in 
many countries. Recently completed phase III trials for bevacizumab and cilengitide in the 
first-line setting will define the future role of these agents. This intense clinical trial activity 
reflects the hope that antiangiogenic agents will become part of the limited therapeutic options 
for glioblastoma. 
Keywords: Aflibercept, Angiogenesis, Bevacizumab, Cediranib, Cilengitide, Clinical trials, 
Enzastaurin, Glioma, VEGF, XL-184 
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1. Introduction 
Glioblastoma is the most common and most malignant primary brain tumor in adults. Despite 
advances in the understanding of genetic and biologic characteristics of this tumor, the 
prognosis remains poor with a median survival of approximately 10 months in recent 
population-based studies [1]. Since 2005, the standard of care of newly diagnosed 
glioblastoma includes surgery or biopsy followed by radiotherapy and concomitant and 
adjuvant temozolomide [2]. At tumor recurrence, there is no generally accepted salvage 
therapy. Competing regimens include temozolomide rechallenge commonly using a dose-
intensified regimen [3], nitrosoureas [4, 5] or novel antiangiogenic agents. Since 
glioblastomas are highly vascularized tumors, various agents targeting angiogenesis have 
been tested in clinical trials. Here, we review the preclinical and clinical data on currently 
explored antiangiogenic agents and approaches. 
1.1 Rationales for the use of antiangiogenic agents in glioma 
The formation and development of blood vessels represent pivotal steps during 
embryogenesis. In the adult, physiological angiogenesis is restricted to the maintenance of 
tissue homeostasis and integrity which is required during wound healing, inflammation and 
the menstrual cycle [6]. The pioneers of angiogenesis research suggested that a tumor mass 
cannot exceed a diameter of 0.4 to 1.0 mm without establishing its own vasculature and 
recruiting a vascular network for further tumor growth [7]. Conceptually, the de novo 
formation of blood vessels was defined as vasculogenesis which is mediated by the 
differentiation of precursor cells into endothelial cells whereas angiogenesis represents the 
development of new vessels from a pre-existing vascular network [8]. In the last decades 
several milestones have been reached in the understanding of molecular mechanisms involved 
in this process. 
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1.2 Identification of key molecules in the process of angiogenesis 
Basic and acidic fibroblast growth factor (bFGF/aFGF) which are secreted by various cancer 
cells were among the first signaling molecules shown to induce angiogenesis by stimulating 
the proliferation and differentiation of endothelial cells [9]. The 22 members of the FGF 
family, ranging from 17 to 34 kDa in size and interacting with tyrosine kinase FGF receptors, 
play an important role in multiple physiologic processes of embryonic development and 
wound healing, but can also promote pathologic angiogenesis [10].  
With vascular endothelial growth factor (VEGF), a very potent and more specific angiogenic 
factor was identified, giving further support to the concept that tumors depend on the 
development of new blood vessels. VEGF-A is the predominant and most angiogenic of the 
vascular growth factors and exists in different isoforms derived from alternative splicing of an 
eight exon-bearing pre-mRNA [11]. Beside the proangiogenic isoforms VEGFxxx-a, “xxx” 
indicating the number of aminoacids (VEGF165a, VEGF189a, VEGF206a), also 
antiangiogenic isoforms containing a different c-terminal and named VEGFxxx-b have been 
described [11, 12].  
VEGF-A stimulates proangiogenic signaling via binding to VEGF receptor (VEGFR)-2. The 
activity of VEGFR-2 can be modulated by the co-receptors and VEGF-binding neuropilins 
(NRP)-1 and NRP-2. VEGF is also a ligand of VEGFR-1 which may act as an antagonist of 
angiogenic signaling by trapping VEGF but exhibits simultanously only minor angiogenic 
signaling due to its weak tyrosine kinase activity [13]. The soluble variant of VEGFR-1 
(sVEGFR-1), a truncated about 110 kDa splice variant of the 180 kDa transmembrane 
receptor VEGFR-1, was also been shown to trap VEGF [14]. VEGFR-1- and sVEGFR-1-
related pathways might represent an endogenous control mechanism balancing pro- and 
antiangiogenic signaling in physiologic conditions and potentially aberrant proangiogenic 
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signaling in pathologic conditions like cancer. Of note, hypoxia which represents a major 
stimulatory factor of proangiogenic signaling, downregulates the expression of sVEGFR-1 in 
endothelial cells [15]. Some authors suggest that VEGF-VEGFR-2 signaling may represent an 
autocrine regulation pathway of glioma cells in addition to the paracrine interplay of tumor 
and endothelial cells [16, 17]. Further members of the VEGF family represent VEGF-B and 
placental growth factor (PlGF) which also bind VEGFR-1 and may act as competitive 
antagonists of VEGF-A. Furthermore PlGF has indirect effects on angiogenesis by 
stimulating different cell types to upregulate the production of VEGF-A and other angiogenic 
factors, e.g. FGFs, platelet-derived growth factor (PDGF), stromal cell-derived factor 1 
(SDF1), granulocyte colony-stimulating factor (G-CSF) and matrix metalloproteinase 
(MMP)-9 [18]. PlGF may play an VEGF-independent role in pathologic angiogenesis since 
PlGF inhibition was shown to inhibit tumor growth by targeting tumor vessels of VEGF(R)-
inhibitor resistant tumors [19]. PlGF-related signaling might thus represent an escape pathway 
mediating resistance to anti-VEGF targeted therapies [18, 20]. However, a pivotal role of 
PlGF in angiogenesis has also been disputed. Carmeliet and collegues provided evidence for a 
proangiogenic role in various pathologic conditions, mostly cancer models. Bais and 
colleagues first refuted any significant effect on tumor angiogenesis in 15 models but later 
correlated efficacy of anti-PlGF treatment with VEGFR-1 expression in tumor cells [21-23].  
Beside the VEGF family other pathways and angiogenic factors play a role in the complex 
process of angiogenesis.  Among these, the family of integrins is involved in modulating a 
pro- or antiangiogenic microenvironment. Integrins are membrane-bound heterodimeric 
proteins that can be activated by recognizing ligands of the extracellular matrix (ECM), for 
example laminins or vitronectins. Ligated integrins are involved in the regulation of 
migration, invasion and survival of endothelial cells, a process that is especially important in 
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conditions of tumor angiogenesis [24]. MMPs interacting with integrin signaling contribute to 
this crosstalk between endothelial cells, integrins and the ECM by releasing pro- or 
antiangiogenic factors, i. e. VEGF of FGFs from the ECM via proteolytic cleavage [25].  
After the establishment of vessels a state of quiescence is followed under physiologic 
conditions. However, this state must be able to switch to angiogenic conditions if required, for 
example, in case of wound healing. This system of vessel quiescence, stabilization and, if 
required, destabilization is regulated by the family of angiopoietins (ANG) and its receptors 
Tie-1 and Tie-2. In absence of Tie-1, Tie-2 can be activated by ANG-1 and ANG-2, leading to 
an unresponsiveness to angiogenic signals. In presence of Tie-1 a high ratio of ANG-2/ANG-
1 results in proangiogenic signaling and vice-versa [26].    
1.3 Cellular targets of antiangiogenesis  
The first therapeutic concepts of antiangiogenesis have almost exclusively focused on host-
derived endothelial cells. They have been considered to be a stable element of the tumor 
microenvironment and the risk of developing resistance to therapeutic approaches was of 
minor concern. However, the experience of antiangiogenic therapies in cancer in general and 
especially in glioblastoma tells that resistance occurs both in a constitutive and an acquired 
manner. Constitutive resistance which translates into a lack of response to antiangiogenic 
therapy may be due to multiple proangiogenic pathways acting not only on VEGF signaling, 
but also involving FGF, PlGF, ANG family members and integrins [13]. The mechanisms of 
acquired resistance are even less well understood. Different hypotheses have been developed 
regarding the relationship of endothelial and glioma cells which may at least in part explain 
the phenomenon of acquired resistance. In 2001, Kunkel and colleagues showed that 
inhibiting VEGF-driven angiogenesis resulted in a cooption of preexisting cerebral vessels by 
glioma cells [27]. Another interesting phenomenon, called vasculogenic mimicry, was 
described by El Hallani and colleagues: glioblastoma stem-like cells adapt endothelial cell-
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like properties and exhibit comparable gene expression resulting in part in a 
transdifferentiation into vessel-like structures, e.g. the expression of collagen IV without 
expression of the pan-endothelial cell marker CD34 [28]. Thus angiogenesis and angiogenic 
tumor growth may be, at least in part, independent of the recruitment of endothelial cells and 
independent of endothelial cell-targeted therapy. An even more radical point of view 
represents the concept that endothelial cells forming tumor blood vessels can develop from 
tumor stem-like cells. Data supporting this hypothesis have been provided by several groups 
independently, showing that a subset of endothelial cells within the tumor vessels share 
genetic aberrations which are also found in glioma stem-like cells [29-31]. In addition, the 
tumor cells developed an endothelial phenotype when cultured under endothelial cell 
conditions and in a xenograft mouse model, tumor vessels were shown to be of human origin 
[30]. Of note, VEGF and VEGFR-2 seem to be involved in the transition of “tumor 
endothelial progenitor cells” into endothelium while the prior step of differentiation of stem-
like CD133+ cells is independent of VEGF [29]. Inhibiting VEGF might thus reduce the 
development of tumor-derived endothelial cells. In contrast, Soda and colleagues suggested 
that this transdifferentiation pathway is independent of VEGF in vitro and  may be even 
stimulated by inhibiting VEGF in vivo [31]. Further investigation is required to get a better 
understanding of the complex interplay of glioma and endothelial cells in order to develop 
suitable strategies inhibiting different forms of angiogenesis.  
1.4 Putative mechanisms of action of antiangiogenic therapy 
The most intuitive goal of a therapeutic approach targeting tumor vessels is to deprive the 
tumors of blood supply in order to reduce their capability of growth. The underlying 
mechanism of action would be vascular regression. Another hypothesis represents the concept 
that antiangiogenic therapy leads to a normalization of a formerly chaotic network of vessels, 
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thus facilitating drug delivery and thereby potentially improving the response to other tumor-
specific therapies [32, 33]. Vessel normalization is also likely to reduce an hypoxic tumor 
environment which is one of the key pathologic factors of glioblastoma and may contribute to 
radioresistance. Interestingly, hypoxia also facilitates the conditions for so called “glioma-
initiating cells” to maintain their stem-like phenotype [34]. In the clinic, antiangiogenic 
therapy may induce both vascular normalization and regression effects [35]. 
1.5 Potential side effects and evasion of antiangiogenic therapy 
In parallel with the advances in understanding the molecular mechanisms and therapeutic 
options of tumor angiogenesis serious concerns arose regarding potential side effects of 
antiangiogenic therapy. Kunkel and colleagues first described an evasive phenotype after anti-
VEGFR-targeted therapy in a mouse glioma model which is characterized by an VEGF-
independent growth and the cooption of preexisting cerebral vessels [27]. This was supported 
by several groups reporting an increased invasiveness of tumors after antiangiogenic 
treatment, both in mice and human glioma and also other cancer models [36, 37]. Whether 
this concept of an increased local invasiveness triggered by antiangiogenic agents is clinically 
relevant remains controversial [38, 39].    
2. Candidate antiangiogenic agents for glioblastoma 
Here, we provide an overview about candidate antiangiogenic agents currently tested in phase 
II and phase III trials of glioblastoma. Figure 1 illustrates the different mechanisms of action 
of antiangiogenic agents in the interplay of endothelial cells and glioma cells and table 1 gives 
a short characterization of the different agents including their status in current clinical trials. 
2.1  Bevacizumab 
Preclinical data 
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Bevacizumab, a humanized monoclonal antibody against VEGF (Avastin, Genentech, South 
San Francisco, CA, and Roche, Basel, Switzerland) is currently the most prominent 
antiangiogenic agent in the field of glioblastoma. It exhibits six VEGF-targeting residues 
preventing VEGF from binding to its receptors [40]. First proof of concept regarding indirect 
anti-tumors effect by targeting VEGF with this antibody was provided in an orthotopic glioma 
mouse model without affecting glioma cell viability in vitro [41]. More recently, CD133+ 
stem-like glioma cells were shown to secrete elevated levels of VEGF with a proangiogenic 
impact both on in vitro angiogenesis models and on in vivo glioma xenograft models that 
could be suppressed by bevacizumab [42].  
Clinical data 
The first larger clinical studies using bevacizumab in patients with malignant glioma were 
published in 2007 [43, 44]. Vredenburgh and colleagues reported two cohorts of glioblastoma 
patients, one cohort of 23 patients receiving bevacizumab at 10 mg/kg plus irinotecan every 2 
weeks, the second cohort of 12 patients with bevacizumab at 15 mg/kg every 21 days and 
irinotecan on days 1, 8, 22, and 29 [43]. The dose of irinotecan was 340 mg/m2 in patients 
taking enzyme-inducing antiepileptic drugs (EIAED) and 125 mg/m2 in patients not taking 
EIAED. The encouraging rates for progression-free survival (PFS) of 46% and the 6-months 
overall survival rate of 77% paved the way for further bevacizumab-based regimens in 
clinical trials in glioblastoma [44]. In 2009, Friedman and colleagues published the BRAIN 
trial which later on served to facilitate the accelerated approval of bevacizumab. In this non-
comparative phase II trial, 167 patients with recurrent glioblastoma were randomized to be 
treated with bevacizumab 10 mg/kg every 2 weeks with or without irinotecan [45]. 
Accordingly, strictly speaking, this study explored the addition of irinotecan to bevacizumab 
and not bevacizumab per se. Patients in both arms showed comparative rates for 6-months 
PFS (42.6% for bevacizumab alone versus 50.3% for the combination) and similar median 
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overall survival (9.2 months for bevacizumab alone versus 8.9 months for the combination). 
However, the safety profile of bevacizumab monotherapy was considerably better than in the 
combination arm (46.4% versus 65.8% grade ≥ 3 adverse events) [45]. In parallel, Kreisl and 
colleagues conducted a similar phase II trial treating patients with recurrent glioblastoma with 
10 mg/kg bevacizumab every two weeks, with an option to add irinotecan at progression.  6-
months PFS was 29% and 6-months overall survival rate 57%, with a median overall survival 
of 31 weeks [46]. No patient showed significant benefit from the addition of irinotecan at 
progression under bevacizumab. The safety of bevacizumab as a single-agent is generally 
considered good. The most frequent reported grade 3 and 4 adverse events in the cohorts with 
bevacizumab monotherapy were arterial or venous thromboembolism (6% and 12.5%), 
arterial hypertension (8% and 4%), wound healing (2.4% and 0%), bowel perforation (0 and 
3%) and proteinuria (0 and 3%) [45, 46]. In contrast to initial expectations, bevacizumab as a 
single agent does not lead to a major risk of cerebral hemorrhage in glioma patients. Some 
authors report that the risk may be augmented by concurrent anticoagulation, while others did 
not observe an increase of bleeding events [47, 48]. The comparison regarding the general 
risk of cerebral hemorrhage in glioblastoma with or without bevacizumab and/or 
anticoagulation has not been assessed in a prospective study.  
Based on the response rate and presumed clinical benefit reported in the two above-mentioned 
phase II studies [45, 46], bevacizumab was conditionally approved in 2009 by the US Food 
and Drug Administration and subsequently in many other countries for the treatment of 
recurrent glioblastoma. In contrast, the European Medicines Agency denied the registration of 
the drug since there was no inclusion of a bevacizumab-free control arm in any trial and 
therefore no proven effect on overall survival [49]. Further concerns arose regarding the 
interpretation of the response rates. The response assessment was mainly based on the 
Macdonald radiographic criteria [45, 46] which may be inappropriate to evaluate 
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antiangiogenic therapies since the reduction in contrast-enhancement may reflect a restoration 
of the blood-brain barrier only and not signify anti-tumor growth effects [50]. The results 
from the bevacizumab trials, amongst others, necessitated to include non-contrast-enhancing 
tumor and thus integration of changes in T2-weighted/FLAIR sequences in the response 
assessment in the new RANO criteria. 
The above-mentioned observations of enhanced infiltration as an escape mechanism from 
antiangiogenic therapy provoked an ongoing discussion regarding the patterns of progression 
and failure after bevacizumab. Several authors reported an increased risk of diffuse 
invasiveness after treatment with bevacizumab in high grade glioma patients [39, 51-53]. In 
contrast, there has also been contradictory evidence which suggests no higher incidence of a 
gliomatosis-like phenotype after treatment with bevacizumab [38, 54]. 
The future impact of bevacizumab in the therapy of glioblastoma will depend on the results of 
two large phase III trials in newly diagnosed glioblastoma which have completed accrual and 
will provide prospective data comparing bevacizumab-treated and untreated cohorts. Both the 
registration trial AVAglio (NCT00943826) and the RTOG-0825 trial (NCT00884741) 
evaluate the addition of bevacizumab to standard temozolomide-based radiochemotherapy in 
a similar randomized double-blind protocol with reasonable endpoints of overall survival and 
progression-free survival [55]. In contrast to AVAglio, the RTOG trial did not include 
patients with a stereotactic biopsy and was conducted in the US where bevacizumab was 
freely available at recurrence. The implementation of quality of life assessment in these trials 
will also help to evaluate whether the expected steroid sparing effect translates into improved 
quality of life. A comparison of patients treated with temozolomide-based radiochemotherapy 
plus bevacizumab first-line to historical controls indicated a gain in PFS, but not in OS, that 
was explained by the availability of bevacizumab at recurrence in the US [56]. This may 
indicate that the RTOG 0825 may miss the OS endpoint, too. On the other hand, this may be 
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different with AVAglio which is conducted in many countries where bevacizumab is not 
readily available at recurrence. Of note, these considerations all suppose that bevacizumab 
given at recurrence has an impact on survival. Finally, the data sets will clarify whether 
bevacizumab alters patterns of relapse when given as first-line treatment. 
Interestingly, in contrast to adult glioma patients, a phase II study in pediatric gliomas did not 
show any objective response which suggests different biologic and angiogenic profiles of 
pediatric tumors in this respect [57]. Of note, among adult glioma patients, clinical data 
indicated that bevacizumab shows a better efficacy in elderly patients whose gliomas may be 
more VEGF-dependent [58]. 
2.2 Aflibercept 
Preclinical data 
With the rationale to improve anti-VEGF-targeted therapies, the idea to prevent VEGF from 
interacting with its receptors by administering decoy soluble receptors led to the development 
of aflibercept (Sanofi-Aventis, Paris, France and Regeneron Pharmaceuticals, Tarrytown, 
NY). This drug, also called “VEGF trap”, is a fusion protein exposing both the domain of 
VEGFR-1 and VEGFR-2, thereby “trapping” all isoforms of VEGF-A and PlGF [59].  
Aflibercept showed efficacy in several preclinical models of solid tumors [60-62]. In an 
orthotopic mouse glioma model aflibercept showed a survival benefit both in initial and 
advanced phases of tumor development. However, this study also described the development 
of a VEGF trap-resistant phenotype characterized by progressive tumor growth and increased 
invasiveness [63]. 
Clinical data 
Based on the encouraging preclinical data, a single-arm phase II study in recurrent malignant 
glioma was conducted by the North American Brain Tumor Consortium. 42 patients with 
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recurrent glioblastoma and 16 patients with recurrent anaplastic glioma were treated with 4 
mg/kg every two weeks i. v. aflibercept. The results were disappointing in every aspect. The 
primary endpoint was not met: 6-months PFS was only 7.7% for glioblastoma and 25% for 
anaplastic glioma patients. In addition, the toxicity of aflibercept, including CNS ischemia 
and systemic hemorrhage, was considerable and 25% of the patients were removed from the 
study for toxicity [64]. After this failure in phase II, aflibercept is not expected to play any 
role in treatment of glioblastoma. However, this may not be generalized to all concepts of co-
targeting VEGF and PlGF which currently are under investigation in clinical trials. Since 
inhibiting VEGF should at least resemble the clinical benefit of bevacizumab and aflibercept 
is supposed to target VEGF, general doubts arise about the efficacy of the compound. 
2.3 Cediranib  
Preclinical data 
Cediranib (AZD2171, Recentin®, AstraZeneca, London, United Kingdom) is an oral ATP-
competitive inhibitor of the tyrosine kinase activity of all VEGF receptors targeting also the 
PDGF and c-Kit receptors [65]. First proof-of-principle was provided both by targeting in 
vivo angiogenesis models via inhibiting endochondral ossification or corpora luteal 
development and by anti-tumor effects in different solid tumor mouse models [66]. In three 
orthotopic mouse glioma models, cediranib-treated mice exhibited a survival benefit which 
occurred despite continuous tumor growth and correlated with a potent reduction of tumor 
edema presumably by vascular normalization effects [67]. Thus, concerns may arise whether 
the postulated antiangiogenic properties of cediranib translate into reduced tumor growth or 
simply reflect a reduced vascular permeability. 
Clinical data 
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First clinical experience with cediranib derived from a phase I study in advanced solid tumors 
describing an acceptable toxicity profile up to an oral daily dose of 45 mg [68]. A small phase 
II study with 16 patients with recurrent glioblastoma, conducted with 45 mg daily, showed a 
clinically relevant effect on tumor edema and MRI-validated potency to induce vascular 
normalization [69]. After completion of the trial, a total of 31 patients were analyzed for a 
primary endpoint of 6-months PFS showing encouraging results of 25.8% and a high 
radiographic response rate as assessed by Macdonald criteria of 56.7% of patients [70]. Based 
on these results, a randomized multicenter phase III trial was conducted to compare the 
efficacy of cediranib alone or in combination with lomustine in recurrent glioblastoma 
(REGAL; NCT00777153). 325 patients were randomized from 67 centers and ten countries 
on a 2:2:1 ratio, 131 patients receiving cediranib monotherapy (30 mg daily), 129 patients the 
combination of cediranib (20 mg daily) and lomustine (110 mg/m2 every 6 weeks), and 65 
patients receiving lomustine and an oral placebo as a control arm [71]. The PFS as primary 
endpoint was disappointing as there was no statistically significant difference of the 
cediranib-containing regimens (median PFS of 92 days for cediranib alone and 125 days in 
combination with lomustine) compared to the median PFS of 82 days of the control group. 
The 6-months PFS of 16% for cediranib monotherapy was considerably lower than the 25.8% 
of the phase II trial. This may be due to a lower dose of cediranib in the phase III trial or 
patient selection. However, the toxicity of 45 mg/day as administered in the phase II trial was 
considerable with 12.9% grade 3/4 toxicities, mainly hypertension, diarrhea and fatigue and 
high percentage (48.4%) of patients requiring drug interruption for toxicity. Nevertheless, 
another prospective randomized trial assessing the efficacy of cediranib has started 
enrollment, conducted by the Radiation Oncology Therapy Group (NCT01062425), to 
explore the addition of cediranib to standard temozolomide-based radiochemotherapy in 
newly diagnosed glioblastoma. 
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2.4  Cabozantinib (XL-184) 
Preclinical data 
Cabozantinib (XL184, Exelixis®, San Francisco, CA) is a dual tyrosine kinase inhibitor 
targeting the receptors MET and VEGFR-2. The MET ligand HGF also binds NRP-1 and thus 
may be related to VEGFR-2 proangiogenic signaling [72]. However, HGF-MET signaling is 
also involved in processes of migration and invasion in glioma and thus represents a 
promising therapeutic target [73]. In a mouse glioma model the proliferation of tumor and 
endothelial cells was reduced, resulting in a dose-dependent inhibition of tumor growth [74]. 
Interestingly, this effect was not associated with an increased metastatic spread in this model 
of lung cancer which has been observed in other approaches targeting VEGF-related 
pathways. 
Clinical data 
Cabozantinib is currently tested in a phase I dose finding study for newly diagnosed 
glioblastoma in combination with the standard therapy and has completed accrual for a phase 
II clinical trial in patients with progressive or recurrent glioblastoma (NCT00704288). 
First results of an interim analysis were presented for 124 patients at ASCO 2010. The study 
was conducted in two cohorts, receiving 125 mg/day or 175 mg/day respectively. The cohort 
with 175 mg/day was reported to have a 6-months PFS of 21 % and an overall response rate 
of 21% in patients without and 8% in patients with prior antiangiogenic therapy. At that time, 
the 6-months PFS for the 125 mg cohort was not yet available. However, the overall response 
rate of the patients without prior antiangiogenic therapy was reported to be 32 %. Further 
evaluation of the risk and benefit is warranted after more follow-up data are available [75]. 
Regarding the toxicity profile the currently only available information from this trial is that 
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125 mg were better tolerated. A previous report of a phase II study in thyroid cancer reported 
a considerable toxicity profile including diarrhea, fatigue, palmar plantar erythrodysesthesia, 
nausea, thromboembolism, mucositis and elevation of liver enzymes [76].   
2.5  Enzastaurin  
Preclinical data 
Enzastaurin HCl (LY317615, Eli Lilly and Company, Indianapolis, Indiana) is an acyclic 
bisindolylmaleimide, acting as a ATP-competitive inhibitor of protein kinase C-β (PKC-β) 
[77]. PKC-β is involved in the downstream signaling of VEGF [78]. The compound showed 
an inhibitory effect on plasma VEGF levels in small lung cancer and renal cell carcinoma 
mouse tumor models suggesting antiangiogenic activity [79]. In human glioblastoma 
orthotopic mouse models Enzastaurin suppressed tumor growth by inducing apoptosis in 
tumor cells and prolonged survival in synergy with irradiation [80, 81].  
Clinical data 
A phase I/II trial was conducted in recurrent glioma with an accrual of 118 patients [82]. In 
the phase I cohorts three dose levels (525 mg, 700 mg, 900 mg) were explored in patients 
receiving EIAED. Therapy was mostly well tolerated and the serum levels of patients on 
EIAED were approximately 80% lower than in those not on EIAED. The most common grade 
3/4 adverse events included thrombosis, thrombocytopenia, hemorrhage and elevated alanine 
aminotransferase levels. In the phase II cohorts, patients not receiving EIAED were treated 
with 500 or 525 mg/day. The radiographic response rates of 84 evaluable patients were at 
25%. Unfortunately this initial response did not translate into a considerable effect on disease 
control as the 6-months PFS was only 7% for patients with glioblastoma and 16% for patients 
with anaplastic glioma. Despite these modest results a phase III trial for patients with 
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recurrent glioblastoma was started comparing 500 mg enzastaurin/day with lomustine (100 to 
130 mg/m2 every 6 weeks) [5]. The enrolment was stopped after 266 of 397 initially planned 
patients since an interim analysis of PFS and OS did not show any significant difference 
between the treatment with lomustine. Median PFS for enzastaurin was at 1.5 months versus 
1.6 months for lomustine and overall survival at 6.1 versus 7.1 months, respectively. In line 
with these disappointing results, a phase II study in patients with newly diagnosed 
glioblastoma exploring the addition of enzastaurin at 250 mg/day to standard temozolomide 
radiochemotherapy did not provide evidence for further benefit [83].  
2.6 Cilengitide 
Preclinical data 
Cilengitide® (Merck KgaA, Darmstadt, Germany) is a synthetic Arginine-Glycine-
Asparagine< (RGD) pentapeptide binding to the RGD ligand binding site on the integrin 
receptors αvβ3 and αvβ5 [84]. This interferes with the communication of integrins with their 
ligands in the extracellular matrix resulting in an impaired signaling to the cell. Inhibiting 
αvβ3 and αvβ5 integrins counteracts VEGF- or FGF-induced endothelial cell invasion and 
differentiation which suggests antiangiogenic activity for cilengitide [85]. Interestingly, tumor 
growth in orthotopic mouse models of glioblastoma and medulloblastoma was inhibited by 
cilengitide, but unaffected in case of subcutaneous implantation [86]. The effect of cilengitide 
thus may be highly context-dependent and cilengitide might modulate the tumor 
microenvironment towards a less permissive angiogenic phenotype. In vitro, cilengitide had 
no significant effect on tumor cell survival or proliferation and did not alter the sensitivity to 
temozolomide or irradiation [87]. However, in vivo, combining cilengitide with radiotherapy 
led to a survival benefit in an orthotopic mouse model compared with either modality alone 
[88]. 
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Clinical data 
The clinical experience in phase I clinical studies demonstrated a favorable safety profile 
without determination of maximum tolerated dose or dose limiting toxicity up to 2400 mg, 
administered intravenously twice weekly [89, 90]. A randomized phase II trial of 81 patients 
with recurrent glioblastoma comparing 500 mg versus 2000 mg cilengitide twice weekly as a 
monotherapy confirmed the excellent tolerability. A trend for a better activity was observed at 
the higher dose of 2000 mg cilengitide with a 6-months PFS of 15% and a median OS of 9.9 
months [91]. However, the activity of cilengitide as a single agent was not considered to be 
sufficient and preclinical data suggested synergistic effects when combining it with irradiation 
[88]. The combination of cilengitide at 500 mg with standard radiation and temozolomide 
therapy in 52 patients with newly diagnosed glioblastoma was assessed in a phase II clinical 
trial. The results were encouraging with a 6-months PFS of 69%, a median overall survival of 
16.1 months and 2-year survival rate of 35%. Striking was a post-hoc subgroup analysis of 
patients with a methylated O6-methylguanine-DNA methyltransferase (MGMT) promotor. 
Preferentially these patients appeared to show the best benefit from the addition of cilengitide 
to the standard of care. The currently most favored hypothesis for this benefit represents the 
idea of a vascular normalization effect leading to an improved delivery of temozolomide to 
the tumor cells. Another phase II trial of cilengitide in newly diagnosed glioblastoma 
randomized patients to 500 mg versus 2000 mg cilengitide in addition to standard 
radiochemotherapy. Data of an interim analysis were presented at ASCO 2009, indicating an 
estimated median survival time of 18.9 months and overall survival at 12 months for all 
patients of 79.5% [92]. The design of subsequent phase III trials has been based on the 
observation of a pronounced benefit for patients bearing the MGMT promotor methylation 
[93].  As the first international multicenter clinical trial the CENTRIC trial incorporated the 
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screening for a molecular marker in the eligibility criteria [94]. Patients with verified 
methylated MGMT promotor were randomized either to the experimental arm receiving 2000 
mg cilengitide in addition to standard radiochemotherapy or to the control arm receiving 
standard therapy alone. After completion of radiochemotherapy maintainance of cilengitide 
was intended to be given for up to 18 months. For patients with an unmethylated MGMT 
promotor a phase II trial, the CORE trial, compares the addition of 2000 mg cilengitide twice 
weekly (Arm 1) or five times a week (Arm 2) during radiotherapy, followed by cilengitide 
maintenance, to standard temozolomide radiochemotherapy alone  (NCT00813943).  
2.7 Other agents 
A detailed characterization of all approaches targeting angiogenesis in glioblastoma would be 
beyond the scope of this review. Briefly, we here summarize some other concepts: 
Chemotherapy in a metronomic, i. e. continuous schedule, is postulated to have an 
antiangiogenic effect by targeting proliferating endothelial cells [95]. In recurrent 
glioblastoma, the activity reported for a temozolomide rechallenge with a continuous dose-
intensified regimen might, at least in part, be explained by an effect on tumor angiogenesis 
[3]. There is also a broad range of small molecules aiming at inhibiting angiogenic pathways 
which were evaluated in phase I/II glioblastoma trials. Among these, the tyrosine kinase 
inhibitors sorafenib and sunitinib so far failed to show relevant activity in recurrent 
glioblastoma, but were associated with considerable toxicity [96, 97]. Temsirolimus 
(Torisel®, Wyeth Pharmaceuticals, Madison, NJ), currently under investigation in phase II 
glioblastoma trials (NCT01019434), is an inhibitor of the phosphoinositide 3-kinase/ 
mammalian target of rapamycin (mTOR) signaling pathway which can be overexpressed in 
glioblastomas and is involved in cell cycle regulation. Based on the experiences in renal cell 
carcinoma an antiangiogenic effect of the drug is postulated [98]. Vascular disruption is a 
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novel concept aiming at completely compromising the established structure of the tumor 
vasculature. In glioblastoma, first experience has been published for the α-tubulin antagonist 
CYT997 which showed vascular disrupting efficacy in preclinical models and in 3 of 6 
evaluable patients in an ongoing phase I study in recurrent glioblastoma [99]. Cerebrovascular 
toxicity was within dose-limiting adverse events and will be of concern in the future 
development of this concept.  
3. Conclusion 
A growing understanding of key mechanisms of angiogenesis led to the development of 
various antiangiogenic agents with activity in preclinical glioma models. However, these 
findings did not always translate into progression or survival benefit in clinical trials. Several 
agents failed to prove efficacy in phase II and phase III trials. The monoclonal antibody 
against VEGF, bevacizumab, was approved as the first antiangiogenic drug in the treatment of 
(recurrent) glioblastoma mainly because of its activity on progression-free survival and a 
presumed clinical benefit. Currently conducted phase III trials for bevacizumab and 
cilengitide will define the future role of these two candidate antiangiogenic agents in 
glioblastoma.  
4. Expert opinion 
Which lessons have we learned from the clinical trials with antiangiogenic therapy in 
glioblastoma? 
First, promising preclinical data often fail to translate into clinical benefit and especially 
survival benefit for patients. Sophisticated therapeutic approaches by small molecule targeting 
of tyrosine kinases and signaling molecules with predictable results in vitro may have 
pleiotropic effects with doubtful results in the complex system of tumor growth and 
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angiogenesis in the clinic. Predicting the mechanism of action and clinical outcome based on 
in vitro and even in vivo models seems more difficult than ever despite advances in our 
understanding of pivotal molecular mechanisms. 
Second, there is more to consider than VEGF and VEGF inhibition in targeting angiogenesis 
in glioblastoma, but still the concepts have to be improved and also to be confirmed. A more 
profound understanding of the molecular mechanisms of angiogenesis led to the entry of 
small molecules like enzastaurin or cediranib into glioblastoma clinical trials, but also these 
agent failed in randomized phase III trials in recurrent glioblastoma. The future role of 
bevacizumab in glioblastoma will depend on the results of the currently conducted phase III 
trials. The conditional approval status of bevacizumab in recurrent glioblastoma in the US and 
many other countries throughout the world might be revised in case of failure in the first-line 
setting. The available phase II data for cilengitide indicate activity of the drug especially in 
patients with MGMT promotor methylation. First results of the phase III trial will be available 
in 2013. 
Third, antiangiogenic agents alone are unlikely to be very effective. However, for 
bevacizumab, so far no clinical trial in glioblastoma showed superiority of a combined 
regimen compared to bevacizumab alone. The addition of cytotoxic agents e.g. irinotecan or 
carboplatin, but also small molecules like erlotinib did not show additional benefit but mostly 
was associated with an unfavorable safety profile [46, 100, 101]. The lack of efficacy may be 
due to the fact that some of the cytotoxic agents that have been applied simply do not have 
activity on glioma cells and thus an increased availability of the drug does not improve their 
efficacy. Second, the effect of vascular normalization may not only affect the intratumoral 
vessels but may also restore a formerly impaired blood-brain barrier which could lead to a 
reduced bioavailability of the drugs. However, the combination of different antiangiogenic 
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agents might be a promising approach based on the current understanding of VEGF-
dependent and VEGF-independent angiogenic signaling. Despite the failure of aflibercept, co-
targeting VEGF and PlGF remains a potential concept to overcome resistance to 
antiangiogenic therapies. A very promising combination partner of bevacizumab but also 
other antiangiogenic agents represents radiotherapy. Since vascular normalization may result 
in an improved oxygenation of the tissue, this is likely to increase the effect of ionizing 
radiation. Preclinical evidence for this concept comes from a mouse glioma model [102]. A 
recent phase II study of 25 patients with recurrent glioma treated with hypofractionated 
radiotherapy plus bevacizumab reported a 6-months PFS of 65%, suggesting activity of this 
concept [103].  
Fourth, clinical trials should have a design which enables valid conclusions implicating 
reasonable endpoints, an appropriate response assessment tailored for the evaluation of 
antiangiogenic therapies and the use of verum-free control arms, that is without the 
investigative agent. [50]. The future design of clinical trials in glioblastoma will depend on 
the outcome of the two large randomized trials for primary diagnosed glioblastoma. The 
approval of either cilengitide or bevacizumab in the first-line setting would strongly affect the 
future design of clinical trials in glioblastoma.  
In conclusion, the intense clinical trial activity reflects the current hope that antiangiogenic 
agents will become part of the still very limited therapeutic options for glioblastoma. 
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Article highlights. 
 Key pathologic features of glioblastoma represent a high vascularity and hypoxic 
tumor microenvironment. In addition, glioma cells express VEGF which plays a 
central role in tumor angiogenesis.  
 Antiangiogenic treatment has entered the clinic in glioblastoma. The VEGF 
antibody bevacizumab is approved in many countries for the treatment of 
recurrent glioblastoma. The majority of current clinical trials focus on various 
antiangiogenic agents, both in newly diagnosed glioblastoma and in recurrent 
disease. 
 Based on preclinical studies and radiographic assessments, one postulated 
mechanism of action of antiangiogenic treatment represents the vascular 
normalization of a formerly disorganized network of vessels. This could lead to a 
better drug delivery and better oxygenation and thereby potentially improved 
response to chemotherapy or irradiation 
 Recent studies raised concerns regarding potential side-effects of antiangiogenic 
treatment in gliomas, especially the development of a proinvasive phenotype. A 
better understanding of the mechanism of action but also of failure of 
antiangiogenic treatment will help to overcome primary or acquired resistance. 
(Co-)Targeting other angiogenic factors beside VEGF or inhibiting pathways 
related to tumor invasion may represent reasonable strategies.  
 There is evidence for activity of some antiangiogenic agents, especially 
bevacizumab and cilengitide, but other agents like aflibercept, cediranib and 
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enzastaurin failed in phase II or phase III trials. However, the effect of the 
currently available antiangiogenic agents may be restricted on improvement of 
progression-free survival and reduction of edema. Recently completed phase III 
trials for newly diagnosed glioblastoma will provide evidence whether 
bevacizumab or cilengitide have an effect on overall survival. 
 
Abbreviations: 
ANG (Angiopoietin), ATP (Adenosine triphosphate), ECM (Extracellular matrix), EIAED 
(Enzyme-inducing antiepileptic drugs), FGF (Fibroblast growth factor), HGF (Hepatocyte 
growth factor), NRP (Neuropilin), OS (Overall survival), PDGFR (Platelet-derived growth 
factor receptor), PKC-β (Protein kinase C-β), PlGF (Placental growth factor), PFS 
(Progression-free survial), RGD (Arginine-Glycine-Asparagine), VEGF (Vascular endothelial 
growth factor), VEGFR (VEGF receptor) 
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Figure 1: Mode of action of antiangiogenic drugs: an overview 
Figure legend:  
Antiangiogenic drugs counteract angiogenic signaling at different extracellular and 
intracellular levels. The monoclonal antibody bevacizumab and receptor fusion protein 
aflibercept inhibit VEGF or VEGF plus PlGF, respectively, in the interaction with their 
receptors. Cilengitide interferes with the interaction of integrins with the ligands of the 
extracellular matrix. Cediranib and cabozantinib (XL-184) inhibit the tyrosine kinase activity 
of their corresponding receptors while enzastaurin targets downstream signaling by inhibiting 
protein-kinase-C-β. 
Abbreviations: BEV (Bevacizumab), ECM (Extracellular matrix), HGF (Hepatocyte growth 
factor), NRP (Neuropilin), PKC-β (Protein kinase C-β), PlGF (Placental growth factor), 
VEGF (Vascular endothelial growth factor), VEGFR (VEGF receptor) 
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Table 1: Salient features of antiangiogenic agents evaluated in clinical trials in glioblastoma 
Agent Mode of action Clinical status Administration Safety profile Ref. 
Bevacizumab Monoclonal 
antibody against 
human VEGF 
preventing the 
interaction of 
VEGF with its 
receptors 
Approved for 
recurrent glioblastoma 
in various countries, 
Phase III for newly 
diagnosed 
glioblastoma 
(AVAglio, 
RTOG0825) 
10 mg/kg every 2 
weeks i.v. 
 
Favorable: 
arterial hypertension, 
thromboembolism, impaired 
wound healing 
[45, 
46] 
Aflibercept IgG fusion 
protein, exhibiting 
domains of 
VEGFR-1 and 
VEGFR-2, 
thereby binding 
VEGF-A and 
PlGF  
 
Phase II in recurrent 
glioblastoma negative 
4 mg/kg every 2 
weeks i.v. 
Considerable: 
CNS ischemias, systemic 
hemorrhage, fatigue, 
thromboembolism, impaired 
wound healing 
[64] 
Cediranib Tyrosine kinase 
inhibitor targeting 
kinases of 
VEGFR-1, -2, -3 
and PDGFR and 
c-Kit impairing 
their signal 
transduction 
Phase III in recurrent 
glioblastoma negative 
(REGAL) 
45 mg/day p.o. 
(phase II), 
30 mg/day p.o. 
(phase III 
monotherapy) 
20 mg/day p.o.  
(phase III 
combination with 
lomustine) 
Considerable: 
hypertension, diarrhea, 
fatigue, elevation of liver 
enzymes 
[70, 
71] 
Cabozantinib Dual tyrosine Phase I/II 125 mg or 175 Safety data for glioma not yet [75, 
kinase inhibitor 
targeting kinases 
of MET and 
VEGFR-2 
impairing their 
signal 
transduction  
mg/day p.o. available; data from a phase II 
trial in thyroid cancer: 
diarrhea, fatigue, palmar 
plantar erythrodysesthesia, 
nausea, thromboembolism, 
mucositis, elevation of liver 
enzymes 
76] 
Enzastaurin ATP-competitive 
inhibitor of 
protein kinase C-
β, inhibition of 
downstream 
signaling of 
VEGF and other 
pathways 
Phase III in recurrent 
glioblastoma negative 
(STEERING) 
525 mg/500 mg 
(phase II) 
250 mg (phase 
III) 
Good: 
thromboembolism, 
thrombocytopenia, 
hemorrhage, elevation of liver 
enzymes 
[5, 82] 
Cilengitide Pentapeptide, 
inhibitor of 
integrins αvβ3 
and αvβ5 by 
binding to their 
RGD binding site 
Phase II in recurrent 
glioblastoma, 
phase III in newly 
diagnosed 
glioblastoma 
(CENTRIC) 
500 mg or 2000 
mg 
Excellent: 
no specific toxicities known  
[89, 
90] 
Abbreviations: ATP (Adenosine triphosphate), PlGF (Placental growth factor), PDGFR (Platelet-derived growth factor 
receptor), RGD (Arginine-Glycine-Asparagine), VEGF (Vascular endothelial growth factor), VEGFR (VEGF receptor) 
 
 
